Latest news with #EV71
Business Wire
4 days ago
- Business
- Business Wire
SINOVAC Board of Directors Files Definitive Proxy Materials
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). In conjunction with the filing of the definitive proxy statement, SINOVAC's Board of Directors mailed a letter to shareholders. In that letter, the SINOVAC Board urged valid shareholders to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. While a dissenting investor group led by Advantech/Prime Success and Vivo Capital (together known as the 'Dissenting Investor Group') is attempting to distract shareholders with false claims and empty promises as part of a hostile attempt to remove the SINOVAC Board and entrench themselves, the SINOVAC Board is committed to restoring fairness and delivering value to ALL SINOVAC shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Business Upturn
5 days ago
- Business
- Business Upturn
SINOVAC Announces New Board Member
Beijing, China: Sinovac Biotech Ltd. (Nasdaq: SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the 'Board') and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board. Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world's largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team's biotech and emerging markets efforts. He has been responsible for overseeing the firm's public equity investments in China since 2009 and the firm's investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company's website at View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
5 days ago
- Business
- Business Wire
SINOVAC Announces New Board Member
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the ' Board ') and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board. Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world's largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team's biotech and emerging markets efforts. He has been responsible for overseeing the firm's public equity investments in China since 2009 and the firm's investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac ®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive ®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive ®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1 ®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu ®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company's website at
Focus Malaysia
06-06-2025
- Health
- Focus Malaysia
Surge in HFMD cases in Malaysia: Key facts and prevention tips
AMID the excitement of school holidays, parents and caregivers should remain extra cautious as the recent surge in Hand, Foot, and Mouth Disease (HFMD) cases reported nationwide underscores the importance of remaining vigilant of the warning signs associated with the illness. Though it is common during this time of the year, Sunway Medical Centre, Sunway City (SMC) paediatric infectious disease consultant Dr Ch'ng Tong Wei said that the current scale of transmission is alarming, necessitating heightened awareness and preventive measures. 'As a paediatric infectious disease specialist, I have observed a rise in hospital referrals, concerned parental inquiries, and requests for guidance from preschools and kindergartens on outbreak management,' she said. Understanding HFMD HFMD is a highly contagious viral infection predominantly affecting children under five. The illness typically presents with: Fever Sore throat Reduced appetite Painful oral ulcers Rash on the hands, feet, and occasionally buttocks Most cases are mild, with recovery within 7–10 days. However, a small number of cases, usually linked to EV71 virus strain, may lead to complications such as: Viral meningitis Encephalitis (brain inflammation) Cardiopulmonary complications. The good news is that these complications remain very rare, she said. Current outbreak situation According to the Health Ministry, HFMD cases throughout sees a 266% increase in infections compared to the same period last year. The number of HFMD cases in Malaysia has risen to 99,601 as of the 17th epidemiological week this year, compared to 27,236 cases during the same period last year. No fatalities were reported linked to the disease. The ministry said 10,421 cases this year or 10% were outbreak-related, while 90% or 89,180 cases occurred sporadically. Prevention tips for parents and schools 'Since there is no specific treatment for HFMD, prevention and comfort care are essential,' she said. The measures to be taken into consideration are: Keep sick children at home Children with HFMD should remain at home until all blisters have dried and they are fever-free for at least 24 hours. This is the most effective way to stop the virus from spreading. Hand-washing is critical. Practice good hygiene Teach children to wash their hands thoroughly with soap, especially after using the toilet and before eating. Disinfect toys and surfaces regularly with chlorine-based or antiviral disinfectants. Avoid high-risk areas during outbreaks Temporarily limit visits to playgrounds, childcare centres, or crowded spaces during outbreaks where transmissions are more likely. Avoid sharing utensils, towels, or personal items. Provide comfort care for infected children Offer soft foods, cool drinks, and administer paracetamol if needed for fever or pain. Seeking medical attention According to Dr Ch'ng, most children recover without complications, but consulting a doctor is paramount if the child exhibits symptoms such as: Refusal to eat or drink (risk of dehydration) High fever (above 39°C) lasting more than 2 days Lethargy, irritability, or altered consciousness Severe cases may require hospitalisation for intravenous hydration, antipyretics, and close neurological monitoring, she added. Curbing HFMD outbreak is a shared responsibility The recent rise in cases across Selangor, Johor, Perak, and other states is a reminder that we must remain vigilant—not just in hospitals, but as a community. We are monitoring the situation closely with its paediatric teams, nurses, and infection control unit are working hand-in-hand to support parents and manage cases safely and efficiently. By staying informed and adopting preventive measures, Dr Ch'ng believes we can collectively reduce transmission and safeguard our children's health. 'Together, we can protect our children and reduce transmission by adhering to the guidelines. For further inquiries or medical advice, please consult a healthcare professional,' she added. ‒ June 4, 2025 Main image: Ovum Hospitals
Barnama
05-06-2025
- Health
- Barnama
Parents, Caregivers Advised To Remain Cautious Of HFMD During School Holidays
KUALA LUMPUR, June 5 (Bernama) -- Parents and caregivers are advised to remain extra cautious following the recent surge in Hand, Foot and Mouth Disease (HFMD) amid the excitement of the school holidays. Sunway Medical Centre, Sunway City (SMC) Paediatric Infectious Disease Consultant Dr Ch'ng Tong Wei said the current scale of transmission is alarming, necessitating heightened awareness and preventive measures. 'As a paediatric infectious disease specialist, I have observed a rise in hospital referrals, concerned parental inquiries and requests for guidance from preschools and kindergartens on outbreak management,' she said in a statement today. She said the recent rise in cases across Selangor, Johor, Perak and other states is a reminder for the public to remain vigilant, not just in hospitals but as a community. 'We are monitoring the situation closely with our paediatric teams, nurses and the infection control unit are working hand-in-hand to support parents and manage cases safely and efficiently,' she said. She said by staying informed and adopting preventive measures, the public can collectively reduce the transmission of the disease and safeguard their children's health. 'Together, we can protect our children and reduce transmission by adhering to the guidelines," she said, adding that parents and caregivers should consult healthcare professionals if they have any inquiries. Ch'ng said the highly contagious viral infection, predominantly affecting children under five, typically presents with fever, sore throat, reduced appetite, painful oral ulcers and rash on the hands, feet and occasionally buttocks. She said that although most cases are mild, with recovery within seven to 10 days, a small number of cases, usually linked to the EV71 virus strain, might lead to complications such as viral meningitis, encephalitis (brain inflammation) and cardiopulmonary complications.
